Literature DB >> 18037989

Overexpression of sPRDM16 coupled with loss of p53 induces myeloid leukemias in mice.

Danielle C Shing1, Maurizio Trubia, Francesco Marchesi, Enrico Radaelli, Elena Belloni, Cinzia Tapinassi, Eugenio Scanziani, Cristina Mecucci, Barbara Crescenzi, Idoya Lahortiga, Maria D Odero, Giuseppe Zardo, Alicja Gruszka, Saverio Minucci, Pier Paolo Di Fiore, Pier Giuseppe Pelicci.   

Abstract

Transgenic expression of the abnormal products of acute myeloid leukemia-associated (AML-associated) primary chromosomal translocations in hematopoietic stem/progenitor cells initiates leukemogenesis in mice, yet additional mutations are needed for leukemia development. We report here aberrant expression of PR domain containing 16 (PRDM16) in AML cells with either translocations of 1p36 or normal karyotype. These carried, respectively, relatively high prevalence of mutations in the TP53 tumor suppressor gene and in the nucleophosmin (NPM) gene, which regulates p53. Two protein isoforms are expressed from PRDM16, which differ in the presence or absence of the PR domain. Overexpression of the short isoform, sPRDM16, in mouse bone marrow induced AML with full penetrance, but only in the absence of p53. The mouse leukemias were characterized by multilineage cellular abnormalities and megakaryocyte dysplasia, a common feature of human AMLs with 1p36 translocations or NPM mutations. Overexpression of sPRDM16 increased the pool of HSCs in vivo, and in vitro blocked myeloid differentiation and prolonged progenitor life span. Loss of p53 augmented the effects of sPRDM16 on stem cell number and induced immortalization of progenitors. Thus, overexpression of sPRDM16 induces abnormal growth of stem cells and progenitors and cooperates with disruption of the p53 pathway in the induction of myeloid leukemia.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18037989      PMCID: PMC2082144          DOI: 10.1172/JCI32390

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  46 in total

1.  Myeloid leukemia-associated nucleophosmin mutants perturb p53-dependent and independent activities of the Arf tumor suppressor protein.

Authors:  Willem den Besten; Mei-Ling Kuo; Richard T Williams; Charles J Sherr
Journal:  Cell Cycle       Date:  2005-11-14       Impact factor: 4.534

2.  Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia.

Authors:  Tatsuya Suzuki; Hitoshi Kiyoi; Kazutaka Ozeki; Akihiro Tomita; Satomi Yamaji; Ritsuro Suzuki; Yoshihisa Kodera; Shuichi Miyawaki; Norio Asou; Kazutaka Kuriyama; Fumiharu Yagasaki; Chihiro Shimazaki; Hideki Akiyama; Miki Nishimura; Toshiko Motoji; Katsuji Shinagawa; Akihiro Takeshita; Ryuzo Ueda; Tomohiro Kinoshita; Nobuhiko Emi; Tomoki Naoe
Journal:  Blood       Date:  2005-06-30       Impact factor: 22.113

3.  p53 and survival in early onset breast cancer: analysis of gene mutations, loss of heterozygosity and protein accumulation.

Authors:  M Gentile; M Bergman Jungeström; K E Olsen; P Söderkvist; S Wingren
Journal:  Eur J Cancer       Date:  1999-08       Impact factor: 9.162

4.  A novel gene, MEL1, mapped to 1p36.3 is highly homologous to the MDS1/EVI1 gene and is transcriptionally activated in t(1;3)(p36;q21)-positive leukemia cells.

Authors:  N Mochizuki; S Shimizu; T Nagasawa; H Tanaka; M Taniwaki; J Yokota; K Morishita
Journal:  Blood       Date:  2000-11-01       Impact factor: 22.113

Review 5.  The yin-yang of PR-domain family genes in tumorigenesis.

Authors:  G L Jiang; S Huang
Journal:  Histol Histopathol       Date:  2000-01       Impact factor: 2.303

6.  Identification of breakpoint cluster regions at 1p36.3 and 3q21 in hematologic malignancies with t(1;3)(p36;q21).

Authors:  S Shimizu; K Suzukawa; T Kodera; T Nagasawa; T Abe; M Taniwaki; F Yagasaki; H Tanaka; S Fujisawa; B Johansson; T Ahlgren; J Yokota; K Morishita
Journal:  Genes Chromosomes Cancer       Date:  2000-03       Impact factor: 5.006

7.  Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations.

Authors:  Konstanze Döhner; Richard F Schlenk; Marianne Habdank; Claudia Scholl; Frank G Rücker; Andrea Corbacioglu; Lars Bullinger; Stefan Fröhling; Hartmut Döhner
Journal:  Blood       Date:  2005-07-28       Impact factor: 22.113

8.  Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease.

Authors:  Susanne Schnittger; Claudia Schoch; Martin Dugas; Wolfgang Kern; Peter Staib; Christian Wuchter; Helmut Löffler; Cristina Maria Sauerland; Hubert Serve; Thomas Büchner; Torsten Haferlach; Wolfgang Hiddemann
Journal:  Blood       Date:  2002-07-01       Impact factor: 22.113

9.  Bethesda proposals for classification of nonlymphoid hematopoietic neoplasms in mice.

Authors:  Scott C Kogan; Jerrold M Ward; Miriam R Anver; Jules J Berman; Cory Brayton; Robert D Cardiff; John S Carter; Sherri de Coronado; James R Downing; Torgny N Fredrickson; Diana C Haines; Alan W Harris; Nancy Lee Harris; Hiroshi Hiai; Elaine S Jaffe; Ian C M MacLennan; Pier Paolo Pandolfi; Paul K Pattengale; Archibald S Perkins; R Mark Simpson; Mark S Tuttle; Joanne F Wong; Herbert C Morse
Journal:  Blood       Date:  2002-07-01       Impact factor: 22.113

10.  Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes a murine model of human t(8;21) acute myeloid leukemia.

Authors:  Masakazu Higuchi; Darin O'Brien; Parasakthy Kumaravelu; Noel Lenny; Eng-Juh Yeoh; James R Downing
Journal:  Cancer Cell       Date:  2002-02       Impact factor: 31.743

View more
  38 in total

1.  A functional screen to identify novel effectors of hematopoietic stem cell activity.

Authors:  Eric Deneault; Sonia Cellot; Amélie Faubert; Jean-Philippe Laverdure; Mélanie Fréchette; Jalila Chagraoui; Nadine Mayotte; Martin Sauvageau; Stephen B Ting; Guy Sauvageau
Journal:  Cell       Date:  2009-04-17       Impact factor: 41.582

Review 2.  The emerging functions of the p53-miRNA network in stem cell biology.

Authors:  Chao-Po Lin; Yong Jin Choi; Geoffrey G Hicks; Lin He
Journal:  Cell Cycle       Date:  2012-06-01       Impact factor: 4.534

3.  Prdm16 is a critical regulator of adult long-term hematopoietic stem cell quiescence.

Authors:  Kristbjorn O Gudmundsson; Nhu Nguyen; Kevin Oakley; Yufen Han; Bjorg Gudmundsdottir; Pentao Liu; Lino Tessarollo; Nancy A Jenkins; Neal G Copeland; Yang Du
Journal:  Proc Natl Acad Sci U S A       Date:  2020-12-02       Impact factor: 11.205

4.  Prdm16 is a physiologic regulator of hematopoietic stem cells.

Authors:  Francesca Aguilo; Serine Avagyan; Amy Labar; Ana Sevilla; Dung-Fang Lee; Parameet Kumar; Ihor R Lemischka; Betty Y Zhou; Hans-Willem Snoeck
Journal:  Blood       Date:  2011-02-22       Impact factor: 22.113

Review 5.  The p53 tumor suppressor protein regulates hematopoietic stem cell fate.

Authors:  Takashi Asai; Yan Liu; Narae Bae; Stephen D Nimer
Journal:  J Cell Physiol       Date:  2011-09       Impact factor: 6.384

6.  Functional relevance of genes predicted to be affected by epigenetic alterations in atypical teratoid/rhabdoid tumors.

Authors:  Isabel Tegeder; Katharina Thiel; Serap Erkek; Pascal D Johann; Johannes Berlandi; Venu Thatikonda; Michael C Frühwald; Marcel Kool; Astrid Jeibmann; Martin Hasselblatt
Journal:  J Neurooncol       Date:  2018-11-16       Impact factor: 4.130

7.  Two novel SNPs in the coding region of the bovine PRDM16 gene and its associations with growth traits.

Authors:  J Wang; Z J Li; X Y Lan; L S Hua; Y T Huai; Y Z Huang; L Ma; M Zhao; Y J Jing; H Chen; J Q Wang
Journal:  Mol Biol Rep       Date:  2010-01       Impact factor: 2.316

Review 8.  Adipose tissue plasticity from WAT to BAT and in between.

Authors:  Yun-Hee Lee; Emilio P Mottillo; James G Granneman
Journal:  Biochim Biophys Acta       Date:  2013-05-17

9.  Downregulation of Prdm16 mRNA is a specific antileukemic mechanism during HOXB4-mediated HSC expansion in vivo.

Authors:  Hui Yu; Geoffrey Neale; Hui Zhang; Han M Lee; Zhijun Ma; Sheng Zhou; Bernard G Forget; Brian P Sorrentino
Journal:  Blood       Date:  2014-07-31       Impact factor: 22.113

10.  Initiation of myoblast to brown fat switch by a PRDM16-C/EBP-beta transcriptional complex.

Authors:  Shingo Kajimura; Patrick Seale; Kazuishi Kubota; Elaine Lunsford; John V Frangioni; Steven P Gygi; Bruce M Spiegelman
Journal:  Nature       Date:  2009-07-29       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.